CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2-  advanced breast cancer with impending or established visceral crisis

ConclusionIn this retrospective study, patients with ER+/HER2- ABC and IVC/VC treated with CDK4/6i had a significantly better survival compared to those treated with weekly paclitaxel. Further prospective studies that minimise possible selection bias are recommended.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research